Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, FL, discusses the results of a Phase II study (NCT01572480) of carfilzomib, lenalidomide and dexamethasone therapy as early intervention, followed by lenalidomide maintenance in high-risk smoldering multiple myeloma (SMM). The results show a favorable benefit-risk profile and warrant further investigation of the regimen in the SMM setting. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.